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Open access under the ElHaloperidol is the most widely used antipsychotic drug in the treatment of psychiatric disorders. Despite
its satisfactory therapeutic effect, its chronic use is related to severe motor side effects. Here, we inves-
tigate the incidence of motor side effects of haloperidol-loaded nanocapsules when compared to free hal-
operidol and the relation with oxidative stress (OS) development. Both vehicle (B-NcFO) and haloperidol
loaded polysorbate-coated nanocapsules suspension (H-NcFO) prepared with ﬁsh oil as core showed uni-
form and rounded particles, nanometric size, negative zeta potential, low polydispersity indices and high
encapsulation efﬁciency. Wistar rats received a single dose of free haloperidol (FH), B-NcFO or H-NcFO
(0.2 mg/kg ip) and were submitted to acute motor side effects evaluation 1 h after the injection. Lower
catalepsy time and oral dyskinesia were observed in H-NcFO-treated group than in FH group; however,
both formulations decreased animals’ locomotor activity. In a experiment performed subchronically, rats
injected daily with H-NcFO (0.2 mg/kg-ip) for 28 days showed decreased oral dyskinesia frequency and
catalepsy time and no impairment on locomotor activity as compared to FH group (0.2 mg/kg-ip). FH
group showed higher OS, as observed by increased lipid peroxidation and reduced glutathione levels
and catalase activity in extrapyramidal region. Our ﬁndings showed that nanocapsules may be an efﬁ-
cient form to prevent or minimize haloperidol motor side effects, which are related to OS development,
ameliorating psychiatric patients’ quality of life.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction ognized for its potency, speciﬁcity and long action (MutschlerHaloperidol is a typical antipsychotic drug used in the treat-
ment of schizophrenia, mania and neurological disorders and rec-O, blank polysorbate-coated
loperidol; FO, ﬁsh oil; GSH,
sorbate-coated nanocapsules
MDA, malondialdehyde; OD,
bituric acid reactive species;
s chewing movement.
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sevier OA license.et al., 1995). Its mechanism of action is mediated by blockade of
D2 dopamine receptors in brain (Creese et al., 1996).
The antipsychotic efﬁcacy of haloperidol is somewhat compro-
mised by the tendency to cause acute and chronic extrapyramidal
movement disorders such as parkinsonism, akathisia, dystonias,
and tardive dyskinesia, which is characterized by repetitive, often
irreversible and disabling involuntary movements (Andreassen
and Jorgensen, 2000). Haloperidol and its metabolites also produce
abnormal movements in animals, e.g., oral dyskinesia (OD), which
has been associated with morphological alterations and oxidative
stress (OS) in extrapyramidal brain regions (Andreassen and
Jorgensen, 2000; Burger et al., 2006; Fachinetto et al., 2007; Naidu
et al., 2003). In this sense, the pathophysiology of movement
disorders induced by haloperidol has been related to oxidative
damage (Burger et al., 2006, 2005a) and neurotoxicity, which are
closely related to increase of turnover rate of dopamine (by block-
ade of presynaptic receptors), leading to production of reactive
substances as a by-product of its metabolism (Andreassen and
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oxidative damage when compared to other organs or systems
(Halliwel and Gutteridge 1999), mainly because it contains high
levels of membrane lipids, excitotoxic amino acids, low levels of
antioxidant defenses, and autoxidizable neurotransmitters. Exper-
imentally, several studies conducted in our laboratory have shown
a relationship between haloperidol-induced movement disorders
and OS, as well as beneﬁcial effects of antioxidant compounds
(Barcelos et al., 2010; Burger et al., 2006, 2005a; Colpo et al.,
2007; Trevizol et al., 2011).
Although more recent atypical neuroleptics do not cause extra-
pyramidal motor disorders, their clinical use remains restricted to
a minority of patients because of their high cost, body weight gain,
and development of diabetes and blood dyscrasias requiring inten-
sive monitoring (Meltzer et al., 1995). For these reasons, typical
neuroleptics such as haloperidol are still the most widely used
antipsychotic drugs in treatment of schizophrenia and other psy-
chiatric disorders (Ponto et al., 2000).
Polymeric nanoparticles have attracted considerable attention
as potential drug delivery systems, increasing therapeutic efﬁcacy
and reducing side effects of a variety of drugs associated with these
systems (Beck et al., 2005, 2006; Bernardi et al., 2009; Mora-Huer-
tas et al., 2010). Polymeric nanoparticles present a size ranging
from 10 to 1000 nm and are employed to carry drugs by incorpo-
ration or absorption (Garcia-Garcia et al., 2005). Carried by nano-
particles, drugs can be released at controlled rates and to speciﬁc
body sites to obtain accurate delivery, which will enhance their
therapeutic efﬁcacy and reduce their toxicity and side effects (Kre-
uter et al., 2002; Mohanraj and Chen, 2006).
Polysorbate-coated nanoparticles were previously reported as
efﬁcient carriers capable of transporting the loaded drugs across
blood–brain barrier (BBB) after administration, being interesting
drug delivery systems to the brain (Bernardi et al., 2010, 2009;
Xin-Hua et al., 2011; Wang et al., 2009). Furthermore, polymeric
nanoparticles can be used as parenteral controlled release systems
to prolong the availability of drugs that freely penetrate the BBB
but have a short duration of action in the central nervous system
(Friese et al., 2000).
It was demonstrated that the association of antipsychotic ris-
peridone with nanoparticles prolonged its therapeutic effect and
reduced catalepsy time in mice (Muthu and Singh, 2008; Muthu
et al., 2009). Recently we reported better therapeutic efﬁcacy and
longer time of action by haloperidol nanocapsules in a pseudo-psy-
chosis animal model (Benvegnú et al., 2011). Moreover, this formu-
lation also caused minor acute and subchronic extrapyramidal side
effects, as observed by reduction of OD and shorter time of cata-
lepsy in rats. In addition, since extrapyramidal motor side-effects
are related to haloperidol treatment, in the present study we aimed
to observe the acute and subchronic motor side effects induced by
free and nanoencapsulated haloperidol and their relationship to OS
markers in dopaminergic brain regions involved in the develop-
ment of movement disorders. For this, we developed haloperidol-
loaded polysorbate-coated nanocapsules containing ﬁsh oil (FO)
rich in n-3 fatty acids, whose antiapoptotic actions (Bazan, 2007)
have shown beneﬁcial effects in animal models of movement dis-
orders (Barcelos et al., 2011, 2010) We hypothesized that this hal-
operidol nanoformulation may be an alternative to overcome some
drawbacks associated with the therapeutic use of free haloperidol.2. Materials and methods
2.1. Chemicals
Haloperidol was obtained from Galena (Campinas-SP, Brazil).
Fish oil capsules (Achè-Guarulhos-SP, Brazil), containing 1 g oil/capsule with 120 mg of DHA and 180 mg of EPA were used.
Poly(e-caprolactone) and sorbitan monostearate (Span 60) were
obtained from Sigma (Tatuapé-SP, Brazil). Polysorbate 80 was ac-
quired from Delaware (Porto Alegre, RS, Brazil). All other chemicals
and solvents used were of pharmaceutical or HPLC grade and used
as received.
2.2. Animals
Wistar adult male rats (200 ± 50 g) were kept in Plexiglas cages
with free access to food and water in a room with controlled tem-
perature (22–23 C) and on a 12 h-light/dark cycle with lights on at
7:00 am. The experimental protocol of this study was approved by
Animal Ethical Committee of Universidade Federal de Santa Maria
(CIETEA-22/2010), which is afﬁliated to CONCEA, and was adhered
to the ‘‘Principles of Laboratory Animal Care’’ (NIH publication) and
international rules of ethics in research.
2.3. Preparation of haloperidol-loaded polysorbate-coated
nanocapsules suspensions containing ﬁsh oil
Nanocapsules (H-NcFO) were prepared by interfacial deposition
of preformed polymer, as described by Fessi et al. (1989). Brieﬂy,
the organic solution consisted of FO (0.8 mL), poly(-caprolactone)
(250 mg), haloperidol (6.3 mg), sorbitan monostearate (192 mg)
and acetone (67 mL), which were poured under magnetic stirring
into an aqueous solution (134 mL) containing polysorbate 80
(192 mg). Acetone was removed and the suspension concentrated
by evaporation under reduced pressure. The ﬁnal volume of the
suspension was adjusted to 25 mL (0.25 mg/mL of haloperidol).
Blank nanocapsules (B-NcFO) were prepared using the same proto-
col described above, but omitting the presence of the drug. Halo-
peridol free suspension (0.25 mg/mL) was prepared in an
aqueous solution using 5% (w/v) of polysorbate 80.
2.4. Physicochemical characterization of nanocapsules
Particle sizes and polydispersity indices (n = 3) were measured
by photon correlation spectroscopy after adequate dilution
(1:500 v/v/) of an aliquot of the suspension in distilled water (Zeta-
sizer Nanoseries ZEN 3600, Malvern Instruments, UK). Zeta poten-
tial was determined using the same equipment, but after dilution
of the samples in 10 mmol L1 NaCl aqueous solution. Drug con-
tent (mg/mL) was determined (n = 3) after dissolution of nanocap-
sules in acetonitrile (1 mL of suspension to 5 mL of acetonitrile)
and assayed by high performance liquid chromatography (HPLC),
according to previously described and validated protocol (Ben-
vegnú et al., 2011), using a Shimadzu instrument (LC-10AVP Pump,
UV–VIS SPD-10AVP Module, Class-VP Software, Shimadzu, Tokyo,
Japan). Encapsulation efﬁciency was determined by the ultraﬁltra-
tion-centrifugation technique. So, the concentration of free drug
was determined in the clear supernatant after this technique
(Ultrafree-MC 10,000 MW, Millipore, Bedford, USA). Encapsula-
tion efﬁciency (%) was calculated by the difference between total
and free drug concentrations determined in the nanocapsule sus-
pension (drug content) and in the ultraﬁltrate, respectively, using
the HPLC method described above. pH values of suspensions were
determined by immersion of the electrode directly in the suspen-
sion using a calibrated potentiometer (MPA-210 Model, MS-Tecno-
pon, São Paulo, Brazil), at room temperature. In addition, the
morphological analysis was conducted by transmission electron
microscopy (TEM; Jeol, JEM 1200 Exll, Centro de Microscopia Elet-
rônica, UFRGS) operating at 80 kV. For this analysis, the diluted
suspension was deposited in Formvar-Carbon support ﬁlm on
specimen grid (electron microscopy sciences) and negatively
stained with 2% (w/v) uranyl acetate solution.
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2.5.1. Experiment 1: Motor side effects induced by acute haloperidol
administration
Twenty-eight rats were randomly divided in four groups (n = 7),
and treated with single injection (ip) of aqueous solution contain-
ing polysorbate 80 5% (v/v) (negative control, group-C), haloperidol
aqueous dispersion (free haloperidol, group-FH), blank nanocap-
sules (blank nanocapsules, group-B-NcFO) and haloperidol-loaded
nanocapsules (haloperidol nanocapsules, group-H-NcFO). All sus-
pensions were administered in the dose of 0.2 mg/kg-ip and the
behavioral tests were performed one hour after the administration,
according to the methodology described below:
2.5.1.1. Oral dyskinesia. Animals were individually placed in cages
(20  20  19 cm3) containing one mirror under the ﬂoor and
one behind the back wall of the cage to allow behavioral quantiﬁ-
cation when the animal was facing away from the observer. To
quantify the occurrence of oral dyskinesia, the incidence of vacu-
ous chewing movement frequency (VCM) was recorded for three
sets of 5 min with 5-min intervals. Observers were blind to the
treatment. In a preliminary study (using ﬁve control and ten halo-
peridol-treated rats) of interrater reliability, we found that the use
of this method of observation and deﬁnition for the parameters
evaluated usually results in 94% agreement between three differ-
ent observers.
2.5.1.2. Locomotor activity. In order to evaluate the reduction of
haloperidol-induced motor activity, rats’ spontaneous locomotor
activity was quantiﬁed just after the ﬁrst interval of oral dyskine-
sia. Animals were placed individually in the center of an open-ﬁeld
arena (40  40  30 cm) with black plywood walls and a white
ﬂoor divided into nine equal squares, as described by Kerr et al.
(2005). The number of lines crossing and the number of rearings
was recorded for 5 min. The crossing and rearing numbers were
indicators of locomotor and exploratory activity, respectively.
2.5.1.3. Catalepsy time. This behavioral test was adapted from Ro-
cha et al. (1997). Catalepsy was measured using a wire grid
(25  9  30 cm2) inclined 45 relative to the bench top. This
behavioral parameter is characterized by positional passivity,
which is observed through failure to correct an uncomfortable im-
posed posture. Each rat was placed with its forepaws near the edge
of the grid and the amount of time spent in this atypical position
was recorded for three times, with an interval of 5 min between
them. All the rats treated with haloperidol (group FH and group
H-NcFO) were individually placed on the inclined grid and ob-
served for 60 s. At the end of the three replications, the mean time
spent by the rat without moving was calculated for each test.
2.5.2. Experiment 2: Motor side effects induced by subchronic
haloperidol administration and oxidative stress markers
Twenty-eight rats were randomly divided in the same four
groups (n = 7) described above (C, B-NcFO, FH and H-NcFO). All
drugs were administered (ip) in the dose of 0.2 mg/kg/mL once a
day, for 28 consecutive days. The same behavioral tests (oral dys-
kinesia, catalepsy time and locomotor activity) described above
were performed 7, 14, 21, and 28 days after treatment initiation,
immediately before administration of suspensions.
At day 29 animals were euthanized by cervical decapitation
after anesthesia with sodium pentobarbital (50 mg/kg body
weight-ip). Brains were removed and cut coronally at the caudal
border of the olfactory tubercle. Cortex, hippocampus and striatum
were removed; Posterior areas containing the right and left sub-
stantia nigra were carefully dissected according to the coordinates
of the Atlas (Paxinos and Watson, 2007): Anterior-posterior (AP)4 to 6 mm; dorsal–ventral (DV) 7–8.8 mm; lateral (L) 2–
3 mm, using external landmarks as delimiters of the region. Dis-
sected nigral area, cortex, hippocampus and striatum were homog-
enized in 10v (w/v) of 0.1 M Tris–HCl, pH 7.4, centrifuged at 1300g
(10 min) and the supernatants were used for OS biomarkers
determination.2.5.2.1. Lipid peroxidation measure. Lipid peroxidation (LP) was esti-
mated by quantiﬁcation of thiobarbituric acid reactive species
(TBARS). LP was measured through the pink chromogen produced
by the reaction of thiobarbituric acid with malondialdehyde (MDA)
at 100 C, measured spectrophotometrically at 535 nm, according
to Ohkawa et al. (1979). Results were expressed as gmol MDA/g
tissue.2.5.2.2. Antioxidant defenses. Reduced gluthatione (GSH) tissue con-
tent was determined after reaction with 5,50-dithiobis-(2-nitroben-
zoic acid). The yellow color formed was read at 412 nm, according
to Boyne and Ellman (1972). A standard curve using cysteine was
used to calculate the content of GSH in tissue samples, expressed
as lmol GSH/g tissue.
Catalase (CAT) activity was spectrophotometrically quantiﬁed
in tissues by the method of Aebi (1984), which involves monitoring
the disappearance of H2O2 in the presence of cell homogenate (pH
7 at 25 C) at 240 nm. The enzymatic activity was expressed in
lmol H2O2/min/g tissue.2.6. Statistical analysis
Data were analyzed by two way ANOVA [(4 (FH/BNcFO/HNcFO/
C)  4 periods of behavioral quantiﬁcations)] followed by Duncan’s
multiple range test, when required. Pearson’s correlation coefﬁ-
cient was calculated between behavioral parameters (VCM, cata-
lepsy, crossing and rearing) and substantia nigra LP (TBARS
levels). Data were analyzed using Statistica (11.0 version) and ex-
pressed as mean ± S.E.M. Signiﬁcance was considered when
p < 0.05.3. Results
3.1. Physicochemical characteristics of polymeric nanocapsules are
shown in Table 1 and Fig. 1
All formulations appeared macroscopically homogeneous and
their aspects were similar to a milky bluish opalescent ﬂuid (Tyn-
dall effect). Both nanocapsule suspensions (B-NcFO and H-NcFO)
presented particles in the submicrometric range (between 200
and 300 nm), low polydispersity (60.25), negative zeta potentials
and neutral pH values (Table 1). The nanometric size population
represents more than 97% of the particle size distribution for both
formulations. Furthermore, H-Nc showed drug content of
0.249 mg/mL and excellent encapsulation efﬁciency
(95.09 ± 0.43%). TEM analysis showed uniform and rounded parti-
cles (Fig. 1).3.2. Motor side effects induced by haloperidol acute treatment
(haloperidol-loaded nanocapsules or free haloperidol) are shown in
Fig. 2
Oral dyskinesia: VCM frequency was increased by 310% after free
haloperidol (FH) administration (p < 0.05) in relation to control (C
group). Both nanocapsule suspensions (H-NcFO and B-NcFO
groups) showed orofacial movements unchanged, which were sim-
ilar to control (Fig. 2A).
Table 1
Physicochemical characteristics of blank and haloperidol loaded-nanocapsules containing ﬁsh oil (B-NcFO and H-NcFO).
Nanocapsules Drug content (mg/mL) Particle size (nm) PDIa (mv) Zeta potential pH
B-NcFO – 290.14 ± 14.4 0.23 ± 0.02 12.43 ± 1.6 7.05 ± 0.2
H-NcFO 0.25 ± 0.002 261.40 ± 3.52 0.21 ± 0.00 13.23 ± 0.7 7.46 ± 0.1
Mean ± S.D.: represents the variation between the different batches (n = 3).
a PDI: polydispersity index.
Fig. 1. Transmission electron microscopy (TEM) images of haloperidol-nanocapsule. A-image on the left: bar = 1200 nm (200.000x); B-image on the right: bar = 50 nm
(400.000x).
626 D.M. Benvegnú et al. / Neurochemistry International 61 (2012) 623–631Catalepsy measurement: In this behavioral evaluation, C and B-
NcFO groups showed no catalepsy. Therefore, they were not in-
cluded in the results and discussion sections. Duncan post hoc tests
showed that H-NcFO treatment led to a decrease in immobility
time (10%) in relation to FH group (p < 0.05) (Fig. 2B).Fig. 2. Acute effect of free or nanoencapsulated haloperidol (0.2 mg/kg, ip). on vacuous ch
(D) numbers in rats (n = 7). These observations were performed 1 h after a single haloper
NcFO-haloperidol-loaded nanocapsules. Data are expressed as mean ± S.E.M (n = 7). ⁄Ind
group (p < 0.05 for all comparisons).Locomotor activity: Haloperidol-treated rats (FH and H-NcFO
groups) demonstrated lower locomotor activity than C group. In
fact, FH and H-NcFO groups presented a decrease of 86% and
84% in crossing and 90% and 84% in rearing, respectively (Fig. 2C
and D).ewing movements (VCM) frequency (A), catalepsy time (B), crossing (C) and rearing
idol administration. C-control; B-NcFO-blank nanocapsules; FH-free haloperidol; H-
icates signiﬁcant difference from C group; +Indicates signiﬁcant difference from FH
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(haloperidol-loaded nanocapsules and free haloperidol) are shown in
Figs. 3 and 4
Oral dyskinesia: Post hoc test showed a signiﬁcant increase in
VCM frequency in FH-treated group in relation to control
(p < 0.05), while both nanocapsule suspensions (H-NcFO and B-
NcFO) did not affect this parameter in animals at all analyzed
times (Fig. 3A). Paired sample T-test indicated that vehicle-(C),
blank nanocapsules-(B-NcFO) and free haloperidol-(FH) treated
rats showed no changes in VCM frequency over time, but be-
tween days 7 and 14, haloperidol-loaded nanocapsules (H-NcFO)
treatment increased this orofacial parameter.
Catalepsy time measurement: H-NcFO-treated rats showed
lower immobility time than FH-treated onesat all analyzed
times (p < 0.05) (Fig. 3B). Paired sample T-test indicates that
H-NcFO group increased catalepsy time at day 28 as compared
to day 7.
Locomotor activity: FH-treated rats showed decreased crossing
and rearing behavior at days 28 and 21, respectively, in relation to
control. Both nanocapsule suspension (B-NcFO and H-NcFO) treat-
ments did not affect locomotor activity in relation to control
(Fig. 4A and B). Paired comparison indicates that FH group showed
a signiﬁcant decrease in crossing at days 21 and 28as compared to
day 7and in rearing at days 21 and 28as compared to days 7 and
14.Fig. 3. Subchronic effects of daily administration of free or nanoencapsulated haloperido
frequency (A) and catalepsy time (B) in rats (n = 7). These observations were perfor
nanocapsules; FH-free haloperidol; H-NcFO-haloperidol-loaded nanocapsules. Data are
treatments at same observed time: ⁄difference from C group; +difference from FH group. L
adifference from 7 day (p < 0.05 for all comparisons).3.4. Oxidative stress and antioxidant defenses parameters of rats
treated with subchronic haloperidol treatment (haloperidol-loaded
nanocapsules and free haloperidol) are shown in Table 2
Duncan post hoc test revealed that FH group showed an in-
crease in TBARS levels in striatum and substantia nigra, a decrease
in GSH levels in striatum and a reduction in CAT activity in sub-
stantia nigra as compared to C group. H-NcFO group showed a de-
crease in TBARS levels in striatum and substancia nigra as well as
an increase in GSH levels in striatum in relation to FH group.
3.5. Correlations of rats treated with subchronic haloperidol
(haloperidol-loaded nanocapsules containing ﬁsh oil and free
haloperidol) are shown in Table 3 or Supplementary Figures 5 and 6
Pearson’s correlation coefﬁcient analyses revealed a signiﬁcant
positive correlation of substantia nigra TBARS levels with VCM fre-
quency and catalepsy duration. In addition, there was a negative
correlation of substantia nigra TBARS levels with locomotor param-
eters (crossing and rearing), conﬁrming that haloperidol-induced
motor disturbances are closely related to OS, veriﬁed through LP.
4. Discussion
Our previous study showed that antipsychotic effects of halo-
peridol-loaded nanocapsules was maintained for longer time andl (0.2 mg/kg/mL-ip once a day, for 28 days) on vacuous chewing movement (VCM)
med at 7, 14, 21 and 28 days after the ﬁrst injection. C-control; B-NcFO-blank
expressed as mean ± S.E.M. (n = 7). Symbols indicate signiﬁcant difference between
etters indicate signiﬁcant difference between observed times in the same treatment:
628 D.M. Benvegnú et al. / Neurochemistry International 61 (2012) 623–631more efﬁcient and the motor side effects were reduced in relation
to free haloperidol (Benvegnú et al., 2011), but up to now no study
had evaluated the oxidative status in extrapyramidal brain regions
of rats treated with this formulation.
Many studies have demonstrated that drug-loaded nanocarriers
are an efﬁcient tool in drug delivery, enhancing therapeutic effects
and reducing adverse side effects (Beck et al., 2005, 2006; Bernardi
et al., 2009; Fontana et al., 2011; Wu et al., 2008). Furthermore,
these systems are able to promote permeation of drugs across
the BBB, as previously demonstrated by several authors (Bernardi
et al., 2009, 2010; Xin-Hua et al., 2011; Wang et al., 2009), suggest-
ing their use as an alternative to haloperidol delivery to the brain.
Here, haloperidol was efﬁciently encapsulated in polymeric
nanocapsules using FO as oily core. The physicochemical proper-
ties of the new formulation are similar to the formulation previ-
ously developed using medium chain triglycerides as oil core
(Benvegnú et al., 2011). So, FO did not have any interference in
the system, showing adequate nanotechnological characteristics
(size, zeta potential, encapsulation efﬁciency and morphology) as
well as drug delivery systems (pH and drug content). Although
the zeta potential can be considered low (in module), it is impor-
tant to highlight that these polymeric suspensions are stabilized
by the presence of the polysorbate layer at the particle/water inter-
face, acting as a steric stabilizer (Jager et al., 2007).
Despite the advances observed in recent years, the mechanism
involved in the transport of drug-loaded polymeric nanocapsuleFig. 4. Subchronic effects of daily administration of free or nanoencapsulated haloperidol
rats (n = 7). These observations were performed at 7, 14, 21 and 28 days after the ﬁr
haloperidol-loaded nanocapsules. Data are expressed as mean ± S.E.M. (n = 7). Symbols in
from C group; +difference from FH group. Letters indicate signiﬁcant difference between
14 (p < 0.05 for all comparisons).into the brain remains uncertain (Garcia-Garcia et al., 2005). Poly-
sorbate 80 could play a special role as anchor between nanoparti-
cles and the apolipoprotein, especially ApoE. Nanoparticles
combined with the apolipoprotein are considered as LDL, and
LDL receptor-mediated transcytosis brings drug-loaded nanoparti-
cles across the BBB (Kreuter et al., 2002). In addition, polysorbate
80 could also inhibit the efﬂux system, especially P-glycoprotein
(Kreuter, 2005), which hinder the access of some drugs into the
central nervous system. However, the exact mechanism involved
in this transport remains unclear.
Motor side effects were monitored after acute and subchronic
haloperidol treatment: Free haloperidol-treated group showed
extrapyramidal side effects, evidenced by increase of OD frequency
and catalepsy time, as well by locomotor impairment, reinforcing
previous reports of our group (Barcelos et al., 2010; Colpo et al.,
2007; Trevizol et al., 2011) and other research groups (Naidu
et al., 2003; Zhang et al., 2007).
Excitotoxicity and OS have been closely related to development
of haloperidol-induced extrapyramidal side effects (Tsai et al.,
1998). In line with this, haloperidol administration can increase
dopamine turnover, which reacts with molecular oxygen to form
dopamine quinones depleting glutathione and generating reactive
species during this process (Andreassen and Jorgensen, 2000). In
addition, blockade of striatal dopamine receptors can increase
extracellular glutamate (Burger et al., 2005b), which in turn
contributes to OS development (Tsai et al., 1998). Then, the(0.2 mg/kg/mL-ip once a day, for 28 days) on crossing (A) and rearing behavior (B) in
st injection. C-control; B-NcFO-blank nanocapsules; FH-free haloperidol; H-NcFO-
dicate signiﬁcant difference between treatments at same observed time: ⁄difference
observed times in the same treatment: adifference from day 7; bdifference from day
Table 2
Sub-chronic effect of free haloperidol or haloperidol-loaded nanocapsules on oxidative stress parameters: thiobarbituric acid reactive substances (TBARS), reduced glutathione
(GSH) and catalase (CAT) different brain regions and liver of rats.
Parameter Tissue C B-NcFO FH H-NcFO
TBARS Cortex 164.91 ± 10.61 167.02 ± 20.20 198.62 ± 7.74 161.67 ± 17.32
Striatum 126.96 ± 09.88 118.37 ± 23.07 177.15 ± 23.97a 97.41 ± 12.33b
Substantia nigra 107.84 ± 18.42 180.33 ± 39.81 342.80 ± 17.51a 179.06 ± 37.86b
GSH Cortex 1.88 ± 0.17 2.16 ± 0.11 1.76 ± 0.29 1.98 ± 0.11
Striatum 1.97 ± 0.11 1.69 ± 0.22 1.12 ± 0.20a 1.83 ± 0.26b
Substantia nigra 1.66 ± 0.36 1.43 ± 0.43 0.94 ± 0.07 1.17 ± 0.24
CAT Cortex 224.44 ± 46.68 163.89 ± 16.05 165.34 ± 2.49 206.42 ± 31.50
Striatum 262.80 ± 41.98 202.85 ± 26.72 210.89 ± 24.69 225.91 ± 25.24
Substantia nigra 342.60 ± 26.50 233.66 ± 26.55 208.19 ± 18.31a 307.72 ± 63.20
Values are expressed as mean ± S.E.M. (n = 7).
C-control; B-Nc-blank nanocapsules; FH-free haloperidol; H-Nc-haloperidol-loaded nanocapsules.
Units-TBARS: mol MDA/g tissue; GSH: mol GSH/g tissue; CAT: lmol H2O2/min/g tissue.
a Indicates signiﬁcant difference from C group.
b Indicates signiﬁcant difference from FH group (p < 0.05 for all comparisons).
Table 3
Linear regression analysis between substantia nigra TBARS levels and behavioral
parameters observed in rats treated with free haloperidol or haloperidol-loaded
nanocapsules containing ﬁsh oil. Linear regression was evidenced by Pearson’s
correlation coefﬁcients (n = 7).
Behavioural parameter R p
Substantia nigra TBARS-VCM 0.599 0.007
Substantia nigra TBARS-Catalepsy 0.708 0.022
Substantia nigra TBARS-Crossing 0.579 0.009
Substantia nigra TBARS-Rearing 0.511 0.025
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induced motor disorders has been intensely studied by our group
(Barcelos et al., 2010; Burger et al., 2005a,b; Colpo et al., 2007;
Teixeira et al., 2011) seeking to better understand the pathophys-
iology of extrapyramidal disturbances induced by typical antipsy-
chotics such as haloperidol, in order to minimize and/or prevent
these symptoms. Of particular importance, ﬁndings of the present
study demonstrated that free haloperidol administration caused a
signiﬁcant LP increase in striatum and substantia nigra, which are
brain regions closely involved in movement disorders. Concomi-
tantly, antioxidant defenses such as GSH levels and CAT activity
were also reduced by free haloperidol treatment in striatum and
substantia nigra, respectively. Contributing to our ﬁndings, a posi-
tive correlation between OD, locomotor activity and catalepsy with
TBARS levels in the substantia nigra were observed, indicating a
causal relationship between oxidative markers and extrapyramidal
side effects. Such correlations reinforce the lower motor impair-
ment induced by nanoencapsulated-haloperidol in relation to free
drug. Taken together, these ﬁndings conﬁrm OS involvement in
development of extrapyramidal disorders such as haloperidol-in-
duced OD. On the other hand, haloperidol loaded-nanocapsules-
caused fewer motor side effects than free haloperidol did, with
no signiﬁcant increase of brain LP or changes in the antioxidant de-
fense system. In fact, recently we showed that haloperidol nano-
capsules was able to increase and prolong its antipsychotic
action, which was accompanied of lower motor side effects (Ben-
vegnú et al., 2011), but until the time no study has compared the
motor side effects induced by FH and HNcFO and their relation-
ships with oxidative damages development in the extrapyramidal
brain area. In fact, different preparations of slow release such as
haloperidol decanoate and osmotic minipumps are currently avail-
able in the antipsychotic therapeutic arsenal, which achieve con-
trolled release and stable plasma levels, but unfortunately, such
formulations remain involved to the development of the long-term
motor side effects. (Taylor, 2009; Andreassen and Jorgensen, 2000;
Hyde et al., 1995). In this sense, researches for new formulationsthat may minimize or delay the serious motor side effects induced
by haloperidol are emerging. Here, we are showing for the ﬁrst
time that the beneﬁcial effects of nanoencapsulated haloperidol
on the motor system may result from lower oxidative damages
in extrapyramidal brain regions, when compared to free drug. In
fact, these brain structures themselves may be key contributors
to OS development, mainly because they are rich in dopamine that
generates reactive metabolites by autoxidation and deamination
(by monoamino oxidase-MAO) (See, 1991).
Considering that haloperidol-loaded nanocapsules showed a
more pronounced activity in a animal model of pseudo-psychosis
(Benvegnú et al., 2011) and that drug-loaded polysorbate 80
coated-nanocapsules reach the brain more efﬁciently than the
non-encapsulated drug (Bernardi et al., 2009; Frozza et al., 2010),
the hypothesis of lower delivery of haloperidol to the brain can
be refuted. Thus, we can suggest two hypotheses: i) alteration in
the distribution of haloperidol in the different brain areas to ex-
plain the decrease in the extrapyramidal motor disorders after
administration of its nanoencapsulated form. This modiﬁed biodis-
tribution could contribute to lower generation of reactive species
and OS, evidenced here by minor LP in these dopaminergic regions;
ii) haloperidol-loaded nanocapsules allow a sustained and contin-
ued delivery of drug, without causing its excessive bioaccumula-
tion in brain extrapyramidal area, differently from FH, whose
brain delivery occurs instantaneously and may generate a burst ef-
fect, facilitating drug accumulation in the same area of the basal
ganglia, and evoking motor side effects, as shown in the present
study. In seeking further information on this, some tests using
HPLC were conducted recently in our laboratory in order to deter-
mine haloperidol brain levels (after free- and nanoencapsulated-
haloperidol treatment), but analytical condition was not sufﬁcient
to detect low levels of the drug in brain (lesser than 100 ng/mL),
indicating inability and unreliability. Thus, there is a need to use
a detector with higher sensitivity and establish new analytical
conditions.
Furthermore, according to different authors, polymeric nano-
particles promote targeted drug delivery (Nagarwal et al., 2009;
Zhu et al., 2009) and higher selectivity and lower systemic side
effects (Beck et al., 2005, 2006; Gao et al., 2010) than the free drug.
However, more studies involving both pharmacokinetic parame-
ters such as biodistribution and tissue levels of haloperidol in brain
dopaminergic areas are needed to conﬁrm one or both the hypoth-
eses proposed here.5. Conclusion
Our study showed that haloperidol loaded-nanocapsules were
able to minimize motor side effects as well as oxidative damages
630 D.M. Benvegnú et al. / Neurochemistry International 61 (2012) 623–631in extrapyramidal brain regions. To our knowledge, this is the ﬁrst
pharmacological study demonstrating beneﬁcial effects of haloper-
idol nanoencapsulation on the oxidative status and related to
behavioral evaluations. We believe that this new polymeric nano-
capsule system can be considered in psychiatry in order to reduce
OS-related movement disorders, ameliorating the quality of life of
patients who need haloperidol. Further studies are necessary to
investigate the haloperidol levels in different brain regions as a
function of time.
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